Investigating a malaria vaccine candidate to improve protection in children
Official title: Analyzing the function and antibody-mediated inhibition of the malaria vaccine candidate PF3D7_1136200
Funded at University of Texas Hlth Science Center · NIH-10824946 · Data updated 2026-11-12
This study is looking at a protein from the malaria parasite to see how it can help create a better vaccine for young children under 5, by figuring out how antibodies against this protein can protect them from malaria.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $41,511 |
| NIH project number | 1F30AI176697-01A1 |
| Project ID | NIH-10824946 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under the age of 5 living in malaria-endemic regions.
✕Less likely to help
Patients who are not children or those living in non-endemic malaria regions may not benefit from this research.
What this research studies
This research focuses on understanding how a specific protein from the malaria parasite, PF3D7_1136200, can help develop a more effective vaccine for malaria, particularly for children under 5 years old. The study aims to analyze how antibodies against this protein can inhibit the malaria parasite and contribute to immunity. By exploring the relationship between antibody responses and protection from malaria, the research seeks to identify ways to enhance vaccine efficacy, especially in regions where malaria is prevalent.
Why it matters
Potential benefit: If successful, this research could lead to a more effective malaria vaccine that significantly reduces the incidence of severe malaria in young children.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting malaria vaccine development, indicating potential for success in this area.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Garza, Rolando — University of Texas Hlth Science Center
- Study coordinator: Garza, Rolando
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.